Study Period | 2019-2032 |
Base Year | 2023 |
Forcast Year | 2023-2032 |
CAGR | 7.99 |
Latest ‘ Favipiravir Market’ Report published by Market Expertz gives a detailed analysis of the significant growth trends seen in the industry due to increasing cases of COVID-19 around the globe. The report also includes valuable information pertaining to the growth of the industry, market dynamics, profit margin, market share assessment, gross revenue, and market estimations for the business vertical for the years 2020 to 2027. The study also traces the competitive scenario in the global market to highlight the prominent players in the industry that control a sizable portion of the total market share, along with their product portfolio and prevalent expansion strategies.
Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Favipiravir was discovered through screening chemical library for anti-viral activity against the influenza virus by Toyama Chemical Co., Ltd. Favipiravir undergoes an intracellular phosphoribosylation to be an active form, favipiravir-RTP (favipiravir ribofuranosyl-5'-triphosphate), which is recognized as a substrate by RdRp, and inhibits the RNA polymerase activity.
Since the catalytic domain of RdRp is conserved among various types of RNA viruses, this mechanism of action underpins a broader spectrum of anti-viral activities of favipiravir. Favipiravir is effective against a wide range of types and subtypes of influenza viruses, including strains resistant to existing anti-influenza drugs. Of note is that favipiravir shows anti-viral activities against other RNA viruses such as arenaviruses, bunyaviruses and filoviruses, all of which are known to cause fatal hemorrhagic fever. These unique anti-viral profiles will make favipiravir a potentially promising drug for specifically untreatable RNA viral infections.
Fujifilm Toyama Chemical has started a Phase III clinical trial of its antiviral influenza drug Avigan (favipiravir) for the treatment of Covid-19 patients in Japan. Avigan specifically blocks RNA polymerase associated with influenza viral replication. The mechanism is expected to have an antiviral effect on SARS-CoV-2, the novel coronavirus that causes Covid-19.
In Japan, the new Phase III trial will assess Avigan’s safety and efficacy as a potential Covid-19 treatment. According to the study data, the drug was able to shorten the recovery time from 11 days to four days for mild and moderate cases.
Generics drugmaker Beximco (AIM: BXP) says its pharmaceutical division and fellow Bangladesh-based Beacon Pharmaceuticals have developed favipiravir, an antiviral drug that is being used by China to treat COVID-19 patients
In this report, the global Favipiravir market is valued at USD xx billion in 2020 and is expected to reach around USD xx billion by the end of 2027, growing at a CAGR of around xx% between 2019 and 2027.
The Favipiravir market study investigates the business sphere and includes scrutiny of the essential aspects that are expected to influence the market outlook. The report consists of key data related to revenue generation, current market scenario, market share, product range, market size, and profit margin estimated for the forecast period.
The report acts as an exhaustive summary of the estimated growth of the market through the forecast years. The industry-wide assessment entails a study of the key market factors that could potentially impact the growth of the market and also projects the growth pattern that the market is expected to exhibit in the forecast duration. The report sheds light on the challenges and hurdles that market players will face in the Favipiravir market in the coming years, underlining the growth prospects prevalent in the market that are speculated to impact the industry trends.
LEADING PLAYERS
The report gives an in-depth assessment of the top companies functioning in the global sector and controlling a sizable portion of the overall market. This section also breaks down the expansion tactics adopted by these companies, along with a detailed assessment of their strategic initiatives by highlighting recent deals, mergers & acquisitions, joint ventures, collaborations, product launches, and technological upgradation. The report creates elaborate company profiles of all leading companies to provide the readers with all relevant data on the competitive landscape, enabling them to capitalize on existing and emerging growth prospects by taking well-informed decisions.
Highlights from the competitive outlook of the Favipiravir market:
Companies engaged in the industry:
Fujifilm Toyama Chemical
Cipla
Hunan Huateng Pharmaceutical Co., Ltd
Lasa Supergenerics Limited
Shouyuan chemical
Zhejiang HISUN Pharmaceuticals Co., Ltd
Toyama Chemica
Critical parameters assessed as part of the competitive landscape in the report:
An extensive analysis of the Favipiravir market with regards to the product landscape and application spectrum:
Product landscape:
20 Tablets/Box
40 Tablets/Box
Key details provided in the report:
Application spectrum:
Hospital
Clinics
Drug Store
Others
Information offered in the report:
The Global Favipiravir Market has been segmented into:
An overview of the information included in the report relating to the geographical indicators:
Key highlights of the Favipiravir market report:
Other essential aspects of the report:
TABLE OF CONTENTS: GLOBAL Favipiravir MARKET
Chapter 1. MARKET SYNOPSIS
1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique
Chapter 2. EXECUTIVE SUMMARY
2.1. Summary Snapshot, 2016 – 2027
Chapter 3. INDICATIVE METRICS
3.1. Macro Indicators
Chapter 4. Favipiravir MARKET SEGMENTATION & IMPACT ANALYSIS
4.1. Favipiravir Segmentation Analysis
4.2. Industrial Outlook
4.3. Price Trend Analysis
4.4. Regulatory Framework
4.5. Porter’s Five Forces Analysis
4.5.1. Power Of Suppliers
4.5.2. Power Of Buyers
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
Chapter 5. Favipiravir MARKET BY TYPE INSIGHTS & TRENDS
5.1. Segment 1 Dynamics & Market Share, 2019 & 2027
5.2. Type 1
5.2.1. Market Estimates And Forecast, 2016 – 2027 (USD Million)
5.2.2. Market Estimates And Forecast, By Region, 2016 – 2027 (USD Million)
5.3. Type 2
5.3.1. Market Estimates And Forecast, 2016 – 2027 (USD Million)
5.3.2. Market Estimates And Forecast, By Region, 2016 – 2027 (USD Million)
Chapter 6. Favipiravir MARKET BY APPLICATION INSIGHTS & TRENDS
6.1. Segment 2 Dynamics & Market Share, 2019 & 2027
6.2. Application 1
6.2.1. Market Estimates And Forecast, 2016 – 2027 (USD Million)
6.2.2. Market Estimates And Forecast, By Region, 2016 – 2027 (USD Million)
6.3. Application 2
6.3.1. Market Estimates And Forecast, 2016 – 2027 (USD Million)
6.3.2. Market Estimates And Forecast, By Region, 2016 – 2027 (USD Million)
6.4. Application 3
6.4.1. Market Estimates And Forecast, 2016 – 2027 (USD Million)
6.4.2. Market Estimates And Forecast, By Region, 2016 – 2027 (USD Million)
6.5. Application 4
6.5.1. Market Estimates And Forecast, 2016 – 2027 (USD Million)
6.5.2. Market Estimates And Forecast, By Region, 2016 – 2027 (USD Million)
Chapter 7. FAVIPIRAVIR MARKET REGIONAL OUTLOOK
7.1. Favipiravir Market Share By Region, 2019 & 2027
7.2. NORTH AMERICA
7.2.1. North America Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.2.2. North America Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.2.3. North America Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.2.4. North America Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.2.5. U.S.
7.2.5.1. U.S. Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.2.5.2. U.S. Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.2.5.3. U.S. Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.2.5.4. U.S. Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.2.6. CANADA
7.2.6.1. Canada Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.2.6.2. Canada Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.2.6.3. Canada Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.2.6.4. Canada Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.3. EUROPE
7.3.1. Europe Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.3.2. Europe Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.3.3. Europe Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.3.4. Europe Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.3.5. GERMANY
7.3.5.1. Germany Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.3.5.2. Germany Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.3.5.3. Germany Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.3.5.4. Germany Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.3.6. FRANCE
7.3.6.1. France Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.3.6.2. France Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.3.6.3. France Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.3.6.4. France Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.3.7. U.K.
7.3.7.1. U.K. Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.3.7.2. U.K. Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.3.7.3. U.K. Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.3.7.4. U.K. Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.4. ASIA-PACIFIC
7.4.1. Asia Pacific Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.4.2. Asia Pacific Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.4.3. Asia Pacific Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.4.4. Asia Pacific Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.4.5. CHINA
7.4.5.1. China Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.4.5.2. China Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.4.5.3. China Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.4.5.4. China Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.4.6. INDIA
7.4.6.1. India Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.4.6.2. India Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.4.6.3. India Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.4.6.4. India Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.4.7. JAPAN
7.4.7.1. Japan Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.4.7.2. Japan Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.4.7.3. Japan Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.4.7.4. Japan Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.4.8. AUSTRALIA
7.4.8.1. Australia Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.4.8.2. Australia Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.4.8.3. Australia Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.4.8.4. Australia Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.5. MIDDLE EAST AND AFRICA (MEA)
7.5.1. Mea Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.5.2. Mea Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.5.3. Mea Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.5.4. Mea Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
7.6. LATIN AMERICA
7.6.1. Latin America Favipiravir Market Estimates And Forecast, 2016 – 2027, (USD Million)
7.6.2. Latin America Favipiravir Market Estimates And Forecast By Segment 1, 2016 –2027, (USD Million)
7.6.3. Latin America Favipiravir Market Estimates And Forecast By Segment 2, 2016 –2027, (USD Million)
7.6.4. Latin America Favipiravir Market Estimates And Forecast By Production Process, 2016 –2027, (USD Million)
7.6.5. Latin America Favipiravir Market Estimates And Forecast By Segment 3, 2016 –2027, (USD Million)
Chapter 8. COMPETITIVE LANDSCAPE
8.1. Market Share By Manufacturers
8.2. Strategic Benchmarking
8.2.1. New Product Launches
8.2.2. Investment & Expansion
8.2.3. Acquisitions
8.2.4. Partnerships, Agreement, Mergers, Joint-Ventures
8.3. Vendor Landscape
8.3.1. North American Suppliers
8.3.2. European Suppliers
8.3.3. Asia-Pacific Suppliers
8.3.4. Rest Of The World Suppliers
Chapter 9. COMPANY PROFILES
9.1. Company 1
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Insights
9.1.4. Strategic Initiatives
9.2. Company 2
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Insights
9.2.4. Strategic Initiatives
9.3. Company 3
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Insights
9.3.4. Strategic Initiatives
9.4. Company 4
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Insights
9.4.4. Strategic Initiatives
9.5. Company 5
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Insights
9.5.4. Strategic Initiatives
9.6. Company 6
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Insights
9.6.4. Strategic Initiatives
9.7. Company 7
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Insights
9.7.4. Strategic Initiatives
9.8. Company 8
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Insights
9.8.4. Strategic Initiatives
9.9. Company 9
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Insights
9.9.4. Strategic Initiatives
9.10. Company 10
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Insights
9.10.4. Strategic Initiatives
A research methodology is a systematic approach for assessing or conducting a market study. Researchers tend to draw on a variety of both qualitative and quantitative study methods, inclusive of investigations, survey, secondary data and market observation.
Such plans can focus on classifying the products offered by leading market players or simply use statistical models to interpret observations or test hypotheses. While some methods aim for a detailed description of the factors behind an observation, others present the context of the current market scenario.
Now let’s take a closer look at the research methods here.
Extensive data is obtained and cumulated on a substantial basis during the inception phase of the research process. The data accumulated is consistently filtered through validation from the in-house database, paid sources as well reputable industry magazines. A robust research study requires an understanding of the overall value chain. Annual reports and financials of industry players are studied thoroughly to have a comprehensive idea of the market taxonomy.
Post conglomeration of the data obtained through secondary research; a validation process is initiated to verify the numbers or figures. This process is usually performed by having a detailed discussion with the industry experts.
However, we do not restrict our primary interviews only to the industry leaders. Our team covers the entire value chain while verifying the data. A significant number of raw material suppliers, local manufacturers, distributors, and stakeholders are interviewed to make our findings authentic. The current trends which include the drivers, restraints, and opportunities are also derived through the primary research process.
The market estimation is conducted by analyzing the data collected through both secondary and primary research. This process involves market breakdown, bottom-up and top- down approach.
Moreover, while forecasting the market a comprehensive statistical time series model is designed for each market. Macroeconomic indicators are considered to understand the current trends of the market. Each data point is verified by the process of data triangulation method to arrive at the final market estimates.
The penultimate process results in a holistic research report. The study equips key industry players to undertake significant strategic decisions through the findings. The report encompasses detailed market information. Graphical representations of the current market trends are also made available in order to make the study highly comprehensible for the reader.
"Find new revenue generation opportunities"